Efficacy results of pimavanserin from a multi-center, open-label extension study in Parkinson's disease psychosis patients

Pimavanserin, a selective 5-HT2A inverse agonist/antagonist, was approved for hallucinations and delusions associated with Parkinson's disease psychosis (PDP). We present durability of response with pimavanserin in patients with PDP for an additional 4 weeks of treatment. This was an open-label...

Full description

Saved in:

Bibliographic Details
Published in:	Parkinsonism & related disorders Vol. 87; pp. 25 - 31
Main Authors:	Isaacson, Stuart H., Ballard, Clive G., Kreitzman, David L., Coate, Bruce, Norton, James C., Fernandez, Hubert H., Ilic, Tihomir V., Azulay, Jean-Philippe, Ferreira, Joaquim J., Abler, Victor, Stankovic, Srdjan
Format:	Journal Article
Language:	English
Published:	England Elsevier Ltd 01-06-2021 Elsevier
Subjects:	Aged Aged, 80 and over Antipsychotic Agents - administration & dosage Antipsychotic Agents - adverse effects Antipsychotic Agents - pharmacology Double-Blind Method Female Humans Male Middle Aged Outcome Assessment, Health Care Parkinson Disease - complications Parkinson Disease - drug therapy Piperidines - administration & dosage Piperidines - adverse effects Piperidines - pharmacology Psychotic Disorders - drug therapy Psychotic Disorders - etiology Urea - administration & dosage Urea - adverse effects Urea - analogs & derivatives Urea - pharmacology
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!